Summary
Proprietary AI platform analyzed multi-omics disease data to identify novel drug candidates and responsive patient subtypes. It narrowed large compound libraries to a focused set of high-potential therapies for laboratory validation. The approach supported development of differentiated, first-in-class assets and advanced candidates into clinical stages. This model aimed to improve discovery efficiency and increase the probability of clinical success.